High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up Journal Article

   

Authors:	Abrey, L. E.; Childs, B. H.; Paleologos, N.; Kaminer, L.; Rosenfeld, S.; Salzman, D.; Finlay, J. L.; Gardner, S.; Peterson, K.; Hu, W.; Swinnen, L.; Bayer, R.; Forsyth, P.; Stewart, D.; Smith, A. M.; Macdonald, D. R.; Weaver, S.; Ramsay, D. A.; Nimer, S. D.; Deangelis, L. M.; Cairncross, J. G.
Article Title:	High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
Abstract:	We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue. This report summarizes the long-term follow-up of the cohort of 39 patients who received high-dose thiotepa with autologous stem cell support. Thirty-nine patients with a median age of 43 (range, 18-67) and a median KPS of 100 (range, 70-100) were treated. Surviving patients now have a median follow-up of 80.5 months (range, 44-142). The median progression-free survival is 78 months, and median overall survival has not been reached. Eighteen patients (46%) have relapsed. Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse. Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding. Long-term neurotoxicity has developed only in those patients whose disease relapsed and required additional therapy; no patient in continuous remission has developed a delayed neurologic injury. This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia. Copyright © 2006 by the Society for Neuro-Oncology.
Keywords:	adult; cancer survival; clinical article; treatment outcome; aged; cancer growth; cancer patient; chemotherapy; drug megadose; neurotoxicity; follow up; antineoplastic agent; multiple cycle treatment; vincristine; autologous stem cell transplantation; lomustine; procarbazine; thiotepa; cancer regression; cancer relapse; oligodendroglioma; anaplastic oligodendroglioma; anaplastic; nervous system injury
Journal Title:	Neuro-Oncology
Volume:	8
Issue:	2
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2006-04-01
Start Page:	183
End Page:	188
Language:	English
DOI:	10.1215/15228517-2005-009
PROVIDER:	scopus
PMCID:	PMC1871935
PUBMED:	16524945
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-33744454934&partnerID=40&md5=7f83f65261e018d3efac8e11eb3f6f2b
Notes:	--- - "Cited By (since 1996): 21" - "Export Date: 4 June 2012" - "CODEN: NEURJ" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/26858